Boehringer Ingelheim collaboration for treatment of schizophrenia

Saniona and Boehringer Ingelheim GmbH (“Boehringer Ingelheim”) have partnered for the discovery and development of new small molecule therapeutics to restore brain network activity in patients with schizophrenia. By combining Saniona’s expertise in ion channels and related technology platforms with Boehringer Ingelheim’s expertise in research and clinical development and commercialization, we are well positioned to advance new treatment options for schizophrenia.

In July 2018, Boehringer Ingelheim selected the first candidate for preclinical and clinical development, triggering a milestone payment of €4 million to Saniona. The program is in the preclinical development phase and Boehringer Ingelheim is preparing the lead candidate for clinical studies.

Boehringer Ingelheim is responsible for the preclinical and clinical development and has global commercial rights. Saniona is eligible to receive up to €90 million in milestone payments and royalties on worldwide net sales of any resulting products under the collaboration. As of December 2018, Saniona has received a total of €9 million under the collaboration excluding earned income under the research collaboration.

Boehringer Ingelheim, founded in 1885, is one of the world’s 20 leading pharmaceutical companies. The focus of the family-owned company is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.